<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095626</url>
  </required_header>
  <id_info>
    <org_study_id>AP-301-III-001</org_study_id>
    <secondary_id>2013-000716-21</secondary_id>
    <nct_id>NCT02095626</nct_id>
  </id_info>
  <brief_title>Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation</brief_title>
  <official_title>Pilot Study to Investigate the Clinical Effect of Orally Inhaled AP301 on Treatment of Primary Graft Dysfunction (PGD) in Mechanically Ventilated Patients After Primary Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apeptico Forschung und Entwicklung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apeptico Forschung und Entwicklung GmbH</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary
      graft dysfunction after lung transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The changes of the P/F ratio from T0 (time of PGD diagnosis) to day 7 of the treatment or to extubation of the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EVLW</measure>
    <time_frame>7 days or until extubation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of extravascular lung water</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PGD Primary Graft Dysfunction</condition>
  <arm_group>
    <arm_group_label>AP301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP-301</intervention_name>
    <description>orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days</description>
    <arm_group_label>AP301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being a male or female recipient on the AKH`s waiting list for primary single or
             double LuTX

          -  PGD score â‰¥ 1 within 72 hours after LuTX

          -  Informed consent is available

        Exclusion Criteria:

          -  History of clinically relevant allergies or idiosyncrasies to AP301 or any other
             inactive ingredient(s) of the investigational product

          -  Postoperative ECMO support

          -  Paediatric /adolescent recipients (&lt; 18 years)

          -  Lobar transplantation

          -  Retransplantation

          -  Combined solid organ transplants

          -  Participation in other drug trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Klepetko, Univ.Prof.Dr.med.univ.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernhard Fischer, Doz</last_name>
    <phone>0043664143</phone>
    <phone_ext>2919</phone_ext>
    <email>b.fischer@apeptico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Thoracic Surgery MedUni Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Aigner, Ass.Prof.Priv.-Doz. Dr.</last_name>
      <phone>0043140400</phone>
      <phone_ext>5620</phone_ext>
      <email>clemens.aigner@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Graft Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
